EN DE
Watch Invitro International for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Invitro International (IVRO) fair value: what the stock is really worth

As of Nov 5, 2026: fair value (intrinsic value) of Invitro International stock $0.06, price $0.06, upside +12.4%, quality 60 out of 100. Rating: undervalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

II Invitro International logo Thin data Nov 8, 2026

Invitro International

IVRO · US
Undervalued, in an uptrend

The stock costs 11% less than our calculation considers fair.

Fair value $0.0647 · Undervalued
Quality 60/100
Solidly profitable · 13.9% net margin (TTM)
Ranks above peers (8/10)
Even on cautious assumptions the value is 2% above the price ($0.0590).
Weak Growth (revenue 5y −4.5 %/yr in USD)
Negative free cash flow
Narrow moat 37/100 · thin data
Thin data
⚠ Thinly traded
Watch Invitro International for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.3900 $0.0400 Fair Value $0.0647 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range $0.0400 – $0.3900 · fair‑value band $0.0590 – $0.0705 · the $0.0576 price screens below the $0.0647 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Invitro International in your weekly email

Every Wednesday you see whether Invitro International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

InVitro International, Inc. develops test kits for non-animal testing applications in the United States and internationally.

Show moreShow less

Its products include Irritection Assay System, an invitro test, which utilizes the change of relevant macromolecules to predict the ocular and dermal irritancy of chemicals, mixtures, and product formulations; and Corrositex, a non-animal test that determines skin corrosivity based on a biomembrane and chemical detection systems.

The company also provides customized technology services for Irritection Assay System installation and testing process, and independent testing laboratory services for irritancy and corrosivity testing requirements, as well as consultation and assistance services.

Its products are principally used in cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, hazardous waste, and transportation industries. InVitro International, Inc. was incorporated in 1985 and is headquartered in Placentia, California.

Stock analysis

Invitro International (IVRO) currently trades at $0.0576, while our model-based Fair Value estimate is $0.0647, implying the stock looks roughly 11% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $0.0900 per share, and 11 of the 13 models we run sit above the $0.0576 price.

Bear case: the Asset-Based group reads lowest at $0.0500, and 2 of the 13 models stay below the price. Data coverage for this calculation is low.

Scenario range: $0.0590 (bear) to $0.0705 (bull), the price of $0.0576 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Invitro International reported revenue of $879K in FY2025 versus $1.0M in FY2021, a compound −3.3%/yr. Reported net income was $122K in FY2025, compounding +6.2%/yr from FY2021.

Key figures

Market cap $1.3M Micro · P/S ratio 1.52 · Net margin 13.9% · Return on equity 7.6% · Return on assets (EBIT) −0.6% (5-year average) · Operating margin 6.0% · Revenue (TTM) $879K · Revenue growth (YoY) −12.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).

What moves the price

The share trades about 62% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at 12%, IVRO screens cheaper than that median.

Fair Value models

Bear $0.0590 Fair Value $0.0647 Bull $0.0705
Price $0.0576 · Upside +12.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings $0.0600 $0.0600 $0.0800 75
Residual Income $0.0600 $0.0600 $0.0700 71
EPV $0.0600 $0.0700 $0.0700 70
All 13 models by family
DCF Models
Owner Earnings $0.0600 $0.0600 $0.0800 75
Earnings-Based
Graham-Dodd $0.0400 $0.0500 $0.0500 67
EPV $0.0600 $0.0700 $0.0700 70
Multiples
P/E Multiple $0.0900 $0.1200 $0.1500 63
P/S Multiple $0.0700 $0.0900 $0.1200 58
P/B Multiple $0.0600 $0.0800 $0.1000 55
EV/EBIT $0.0600 $0.0800 $0.1000 63
EV/EBITDA $0.0600 $0.0700 $0.0900 64
EV/Revenue $0.0500 $0.0600 $0.0800 52
Asset-Based
NCAV (Graham) $0.0300 $0.0500 $0.0700 51
Economic Profit
Residual Income $0.0600 $0.0600 $0.0700 71
ROIC Compounder $0.0600 $0.0700 $0.0700 70
Growth Earnings
Growth-Adj P/E $0.0600 $0.0900 $0.1200 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 60/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 47
How much profit the company makes from its sales and capital
Quality Growth 58
Are margins and returns getting better?
Cashflow 13
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 76
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 37
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 15
Distance to the 52-week high, does not count
New shares 78
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 17/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+8.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.5%
Start year 2020 (pandemic)
Revenue growth 36 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +13.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+13.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.11.3% vs 0.0%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 10%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 4.5%/yr over ~30Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
⚠ Rate on operating basis: 2025 sits 500% above its own trend.

Watch IVRO, get fair value alerts →

Compare Invitro International with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 8/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 60 · Above median
Fair Value upside +12.3% · Top 25%
Profitability
Return on equity (12 months) 7.6% · Above median
Return on assets 6.1% · Above median
Net margin (12 months) 13.9% · Above median
Operating margin (12 months) 6.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) −12.9% · Bottom 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.77× · Cheapest 25%
P/S (12 months) 1.46× · Cheapest 25%
EV/EBITDA 6.7× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)50 · sector 0
FUTURE (revenue growth)0 · sector 39
PAST (return on equity)30 · sector 15
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥147.00 ¥164.66 +12% vs IVRO
IQVIA Holdings IQV $271.83 $299.01 +10% vs IVRO
Illumina, Inc ILMN $213.13 $228.80 +7% vs IVRO
Thermo Fisher Scientific Inc TMO $694.76 $686.04 −1% vs IVRO
Danaher Corporation DHR $230.25 $209.18 −9% vs IVRO
IDEXX Laboratories, Inc IDXX $676.04 $496.48 −27% vs IVRO
Mettler-Toledo International Inc MTD $1,722 $650.28 −62% vs IVRO
Agilent Technologies, Inc A $174.76 $64.53 −63% vs IVRO
Lonza Group LONN CHF 663.40 CHF 153.50 −77% vs IVRO
Waters Corporation WAT $457.60 $91.26 −80% vs IVRO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Invitro International: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Invitro International Fair Value". https://www.fairvalue-calculator.com/stock/IVRO

Frequently asked questions

Is Invitro International (IVRO) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $0.0647 versus a price of $0.0576, about +12% upside (undervalued).
What is the fair value of IVRO?
Our model-based fair value for Invitro International is $0.0647 (as of Nov 8, 2026), built from audited fundamentals. The current price: $0.0576.
What is the quality score of IVRO?
Invitro International has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Invitro International (IVRO)?
Our model-based price target is the fair value of $0.0647 (as of Nov 8, 2026) from 13 valuation models. Cautious scenario $0.0590, optimistic scenario $0.0705. It is a calculation from audited fundamentals, not an analyst target.
What is the Invitro International stock forecast for 2026?
Our models put fair value at $0.0647, about +12% upside versus a price of $0.0576 (undervalued). Cautious scenario $0.0590, optimistic scenario $0.0705. The calculation is refreshed regularly with new filings.
What is the revenue of Invitro International (IVRO)?
Invitro International reported trailing-twelve-month revenue of about $879K (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Invitro International (IVRO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Invitro International it is $0.0647 per share (as of Nov 8, 2026), against a price of $0.0576. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Invitro International stock overvalued or undervalued in 2026?
As of Nov 8, 2026, IVRO trades below its calculated fair value: price $0.0576, fair value $0.0647, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IVRO?
No. The price is what the market pays today ($0.0576); the fair value is what the company's own numbers justify ($0.0647). For Invitro International the two are $0.0071 per share apart. That gap is exactly why we show both numbers side by side.
How much is Invitro International worth?
The market values Invitro International at about $1.3M (market capitalisation, as of Nov 8, 2026). Per share that is $0.0576; our models calculate a fair value of $0.0647 per share.
What do the bullish and bearish scenarios say about IVRO?
Our models span a range for Invitro International: cautious scenario $0.0590, base $0.0647, optimistic $0.0705 per share (as of Nov 8, 2026, price $0.0576). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Invitro International (IVRO)?
Balance-sheet figures for Invitro International (as of Nov 8, 2026): return on equity 7.6%. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is IVRO from its 52-week high?
Invitro International trades at $0.0576, about 62% below its 52-week high of $0.1500 and 18% above the low of $0.0490 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0647 is for.
Which stocks are comparable to Invitro International?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Invitro International stock attractive at the current price?
The data as of Nov 8, 2026: price $0.0576, calculated fair value $0.0647 (+12%), Quality Score 60/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IVRO calculated?
We run Invitro International through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $0.0647 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Invitro International currently trades 11% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Invitro International (IVRO)?
The closing price on Nov 5, 2026 was $0.0576. Our model-based fair value is $0.0647, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Invitro International right now?
The price is below even our cautious bear case ($0.0590). The market is more pessimistic than our downside scenario. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Invitro International

How large is the market capitalisation of Invitro International (IVRO)?
The market capitalisation of Invitro International is $1.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Invitro International (IVRO)?
The price-to-sales ratio of Invitro International is 1.52 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Invitro International (IVRO)?
The net margin of Invitro International is 13.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Invitro International (IVRO)?
The return on equity (ROE) of Invitro International is 7.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Invitro International (IVRO)?
On an EBIT basis the return on assets of Invitro International is −0.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Invitro International (IVRO)?
The operating margin of Invitro International is 6.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Invitro International (IVRO)?
Revenue at Invitro International is growing −12.9% versus a year earlier (3y avg +1.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Invitro International (IVRO)?
Earnings per share at Invitro International are growing +48.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Invitro International (IVRO) generate?
The free cash flow of Invitro International is −$8.7K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Invitro International (IVRO) hold?
Invitro International holds more cash than debt, $313K net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Invitro International in the live analysis

One click puts Invitro International on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.